A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden
(2011) In Nordic Journal of Psychiatry 65(6). p.13-403- Abstract
BACKGROUND: Atypical antipsychotics have similar clinical efficacy in the treatment of schizophrenia; variability in their tolerability represents the discerning factor in treatment choices. Sertindole has a relatively good tolerability profile that favours long-term patient adherence and, therefore, is associated with lower rates of relapse and rehospitalization.
AIM: A model was developed to compare the cost-effectiveness of a 5-year treatment strategy starting with sertindole versus olanzapine, risperidone, aripiprazole or the typical antipsychotic agent, haloperidol.
METHODS: The model was based on published trials and local clinical practice, and considered costs from the perspective of the Swedish National Health... (More)
BACKGROUND: Atypical antipsychotics have similar clinical efficacy in the treatment of schizophrenia; variability in their tolerability represents the discerning factor in treatment choices. Sertindole has a relatively good tolerability profile that favours long-term patient adherence and, therefore, is associated with lower rates of relapse and rehospitalization.
AIM: A model was developed to compare the cost-effectiveness of a 5-year treatment strategy starting with sertindole versus olanzapine, risperidone, aripiprazole or the typical antipsychotic agent, haloperidol.
METHODS: The model was based on published trials and local clinical practice, and considered costs from the perspective of the Swedish National Health Insurance Board.
RESULTS: All atypical agents were clinically superior and more cost-effective than haloperidol with a cost per quality-adjusted life year gained of approximately 490,000 Swedish kroner. Sertindole was associated with the lowest direct and indirect medical costs, driven by its tolerability profile.
CONCLUSIONS: Sertindole represents a useful alternative to the current treatment options available in Sweden.
CLINICAL IMPLICATIONS: The relatively good tolerability profile of sertindole translates into lower costs of schizophrenia management, primarily driven by substantially lower direct and indirect costs. Sertindole appears to be a clinically and cost-effective alternative in the management of patients with schizophrenia in Sweden.
(Less)
- author
- Lindström, Eva LU ; Eberhard, Jonas LU ; Fors, Björn M ; Hansen, Karina and Sapin, Christophe
- publishing date
- 2011-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adult, Antipsychotic Agents, Aripiprazole, Benzodiazepines, Cost-Benefit Analysis, Economics, Pharmaceutical, Female, Haloperidol, Humans, Imidazoles, Indoles, Male, Models, Economic, National Health Programs, Piperazines, Quinolones, Risperidone, Schizophrenia, Sweden
- in
- Nordic Journal of Psychiatry
- volume
- 65
- issue
- 6
- pages
- 11 pages
- publisher
- Informa Healthcare
- external identifiers
-
- pmid:21770821
- scopus:80055097521
- ISSN
- 1502-4725
- DOI
- 10.3109/08039488.2011.590603
- language
- English
- LU publication?
- no
- id
- 3aef0e35-2ff5-49fd-839f-e5896d6a2be7
- date added to LUP
- 2016-06-22 16:08:22
- date last changed
- 2024-08-23 16:58:45
@article{3aef0e35-2ff5-49fd-839f-e5896d6a2be7, abstract = {{<p>BACKGROUND: Atypical antipsychotics have similar clinical efficacy in the treatment of schizophrenia; variability in their tolerability represents the discerning factor in treatment choices. Sertindole has a relatively good tolerability profile that favours long-term patient adherence and, therefore, is associated with lower rates of relapse and rehospitalization.</p><p>AIM: A model was developed to compare the cost-effectiveness of a 5-year treatment strategy starting with sertindole versus olanzapine, risperidone, aripiprazole or the typical antipsychotic agent, haloperidol.</p><p>METHODS: The model was based on published trials and local clinical practice, and considered costs from the perspective of the Swedish National Health Insurance Board.</p><p>RESULTS: All atypical agents were clinically superior and more cost-effective than haloperidol with a cost per quality-adjusted life year gained of approximately 490,000 Swedish kroner. Sertindole was associated with the lowest direct and indirect medical costs, driven by its tolerability profile.</p><p>CONCLUSIONS: Sertindole represents a useful alternative to the current treatment options available in Sweden.</p><p>CLINICAL IMPLICATIONS: The relatively good tolerability profile of sertindole translates into lower costs of schizophrenia management, primarily driven by substantially lower direct and indirect costs. Sertindole appears to be a clinically and cost-effective alternative in the management of patients with schizophrenia in Sweden.</p>}}, author = {{Lindström, Eva and Eberhard, Jonas and Fors, Björn M and Hansen, Karina and Sapin, Christophe}}, issn = {{1502-4725}}, keywords = {{Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Models, Economic; National Health Programs; Piperazines; Quinolones; Risperidone; Schizophrenia; Sweden}}, language = {{eng}}, number = {{6}}, pages = {{13--403}}, publisher = {{Informa Healthcare}}, series = {{Nordic Journal of Psychiatry}}, title = {{A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden}}, url = {{http://dx.doi.org/10.3109/08039488.2011.590603}}, doi = {{10.3109/08039488.2011.590603}}, volume = {{65}}, year = {{2011}}, }